LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings LLC. Dr. Eshelman is the founder, Vice Chairman and CEO of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), an international contract research organization. Aton is a wholly owned subsidiary of Princeton Pharma Holdings LLC.
"We are delighted that Dr. Eshelman has agreed to join Princeton Pharma Holdings' management board," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is a rare individual -- both an accomplished entrepreneur and an accomplished scientist. He built a very successful enterprise from the ground up and his knowledge of product development is exceptional. His insights are going to provide tremendous value to Aton as we implement our strategic plan."
"Aton is a very interesting specialty pharmaceutical company with their focus on medically essential therapeutics and I'm impressed with the amount of progress they have made in a relatively short period of time," stated Dr. Eshelman. "I look forward to lending my experience and helping this company reach its goals."
Dr. Eshelman's expertise will be helpful as Aton continues to execute its product life cycle management strategy and expand its research program, which includes partnerships with a variety of thought leaders, major medical institutions and research organizations.
Dr. Eshelman's career has included positions as Senior Vice President
of Development and Vice President of Clinical Operations for the former
Glaxo, Inc., as well as various roles in drug development with other
|SOURCE Aton Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved